Table 1.

Table of basic characteristics of included studies.

References	Patient number	Treatment duration (weeks)	Intervention	Number randomized	Disease duration (years)	Age (years)	Male N/(%)
Yang et al. (19)	767	24	Dorzagliatin 75 mg bid Metformin 1,500 mg qd	382	6.14	54.6 ± 10.0	245 (64)
			Placebo bid Metformin 1,500 mg qd	385	5.78	54.4 ± 9.2	230 (60)
Zhu et al. (18)	463	24	Dorzagliatin 75 mg bid	153	1	53.2 ± 9.6	200 (65)
			Placebo bid	310	0.89	53.5 ± 10.0	101 (66)
Zhu et al. (17)	102	24	Dorzagliatin 75 mg bid	49	3.41	55.4 ± 7.7	31 (63)
			Placebo bid	53	3.37	54.7 ± 8.5	31 (58)